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Copyright © 200? JCBN Summary More elderly patients now undergo gastrointestinal endoscopy following recent
advances in endoscopic techniques. In this study, we conducted a high-risk survey of endo-
scopies in Japan, using a questionnaire administered prior to upper gastrointestinal tract
endoscopy (UGITE), and identified anticholinergic agents and glucagon preparations as high-
risk premedication. We also evaluated the cardiovascular effects of anticholinergic agents and
glucagon through measurements of plasma levels of human atrial natriuretic peptide (hANP)
and human brain natriuretic peptide (hBNP). The subjects were 1480 patients who underwent
UGITE. Nurses administered a pre-endoscopy questionnaire, questioning subjects regarding
heart disease, hypertension, glaucoma, and urinary difficulties as risk factors for anticholinergic
agents, and Diabetes mellitus as a risk factor for glucagon preparations. Evaluation of subjects
divided into under 65 and over 65 age groups revealed that in subjects aged 65 and over, risk
factors for anticholinergic agents were significantly more high than those for glucagon.
Analysis of the cardiovascular effects of anticholinergic agents and glucagon, in the elderly
patients showed that hANP levels were significantly higher following administration of
anticholinergic agents, but the change was not significant for glucagon premedication. Taking
a detailed history before UGITE with the aid of a questionnaire at the same time as informed
consent is obtained, is extremely useful in terms of risk management and selection of the
appropriate premedication.
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Introduction
Gastrointestinal endoscopic investigation and treatment
have contributed greatly to improved quality of life for
Japanese patients in recent years, through innovations in
endoscopic techniques, marked improvement in endoscopes
and accessories, and enhancements to the medical insurance
system. Gastrointestinal endoscopy is used in wide variety
of situations, from everyday investigation to highly complex
diagnostic and therapeutic applications. A certain level of
complications appears to be unavoidable; both adverse
drug reactions to antispasmodic premedication, including
allergic reactions and anaphylactic shock, and intraoperative
haemorrhage or perforation [1–4]. Reports from Japan of
endoscopic complications appear regularly in the literature;
in a survey of the age distribution of deaths due to endo-
scopic premedication and endoscopy itself, Kaneko et al.
found a rapid increase in deaths from both causes over the
age of 60 years [5].E. Umegaki et al.
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Accompanying the aging of the general population in
Japan, the proportion of elderly patients undergoing gastro-
intestinal endoscopy is also increasing, making less invasive
and safer investigations desirable from the risk management
point of view. Okamura et al. reported increased use of
antithrombotic therapy in elderly patients, and examples of
inadequate history-taking resulting in hemorrhagic compli-
cations due to an inadequate washout period for the anti-
thrombotic therapy, or no washout at all [6]. The choice of
anticholinergic agents and glucagon, administered as anti-
spasmodic premedication prior to gastrointestinal endo-
scopy, needs to be carefully considered in the elderly
because of the high incidence of conditions such as prostatic
hypertrophy, glaucoma and heart disease, for which anti-
cholinergic agents are contraindicated.
With these considerations in mind, we developed a
questionnaire for assessing patient background factors prior
to gastrointestinal endoscopy, and investigated the propor-
tions of patients with risk factors for anticholinergic agents
and glucagon, and how these correlated with age. We also
evaluated the cardiovascular effects of anticholinergic agents
and glucagon used as premedication in gastrointestinal endo-
scopy.
Subjects and Methods
Patients who underwent upper gastrointestinal tract endo-
scopy (UGITE) at the Osaka Medical College Hospital
Endoscopy Center between June and December 2001 were
included in the retrospective study. The World Health
Organization (WHO) definition of elderly patients, i.e.,
those aged 65 years or older, was used for this study.
A doctor or nurse administered the oral pre-endoscopy
questionnaire, which is shown in Figure 1. The questions
were developed to detect background factors, including
underlying conditions and medication, in each subject to
help in risk management and reducing endoscopy complica-
tions. The <65 (younger) and ≥65 age groups (elderly) were
compared for five characteristics or clinical conditions
deemed high-risk for complications: 1) first-time endoscopy;
Fig. 1. Detail of pre-endoscopy questionnaire developed at Osaka Medical College Gastrointestinal Endoscopy Center.Risk Management for Gastrointestinal Endoscopy
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2) lignocaine allergy; 3) antithrombotic therapy (e.g.,
warfarin, ticlopidine, aspirin); 4) heart disease (arrhythmia,
ischemic heart disease), hypertension, glaucoma, prostatic
hypertrophy; and 5) Diabetes mellitus.
We injected anticholinergic agents (15 mg of prifinium
bromide) or glucagon (1 mg of Glucagon G Novo) mus-
cularly according to Table 1 (Comparison of contraindica-
tions and precautions for use associated with anticholinergic
agents and glucagon used as premedications for gastro-
intestinal endoscopy) and then evaluated the cardiovascular
effects of anticholinergic agents and glucagon through
measurements of plasma levels of human atrial natriuretic
peptide (hANP) and human brain natriuretic peptide (hBNP),
which are indices of cardiovascular load [7,  8]. hANP
and hBNP were measured before and after UGITE using
chemiluminescent enzyme immunoassay (CLEIA) in the
above period, between June and December 2001. The levels
of hANP and hBNP at baseline and after endoscopy were
compared in the <65 and ≥65 age groups, and the elderly
group (≥65 years) was further stratified according to the
presence of cardiovascular disease.
Analysis
All data were expressed as mean ± SD. Analyses were
conducted using Fisher’s exact method (chi-square test) or
Student’s t test, with p<0.05 considered statistically signifi-
cant.
Results
Baseline patient characteristics
The baseline patient characteristics are shown in Table 2.
The study included 1480 patients, of which over half were
aged <65 years.
Analysis of risk groups
Subjects undergoing their first endoscopy. First-time endo-
scopy cases accounted for 26.6% of all subjects and the
proportion of first endoscopy procedures was significantly
lower in the elderly subjects (p = 0.0042, Table 3).
Subjects with lignocaine allergy.  Subjects allergic to
lignocaine accounted for 2.8% (25/883) of subjects aged
<65 years and 1.0% (6/597) of those ≥65 years, making
lignocaine allergy significantly less common in elderly sub-
jects (p = 0.016, Table 3).
Table 1. Comparison of contraindications and precautions for use associated with anticholinergic agents and glucagon used as premed-
ications for gastrointestinal endoscopy
Glucagon Anticholinergic
Contraindications
Patients with suspected pheochromocytoma Patients with haemorrhagic colitis
Patients with glaucoma
Patients with a history of hypersensitivity 
to this drug
Patients with impaired micturition due to prostatic hypertrophy
Patients with serious heart disease
Patients with paralytic ileus
Patients with a history of hypersensitivity to this drug
Patients with bacterial diarrhoea (relative contraindication)
Precautions with use
Patients with an insulinoma Patients with prostatic hypertrophy
Elderly patients with known heart disease Patients with congestive heart failure
Diabetic patients Patients with cardiac arrhythmias
Patients with hepatic disease associated 
with impaired glucose release, such as 
cirrhosis
Patients with ulcerative colitis
Patients with hyperthyroidism
Patients in high temperature environments
Table 2. Baseline patient characteristics
Number of subjects 1480
Age (yrs, mean ± SD) 59.2 ± 14.3
Elderly (over 65 yrs) 40.3% (597)
Gender (M/F) 805/675
First time for endoscopy 26.6% (402)
Lignocaine allergy 2.1% (31)
Antithrombotic therapy 16.6% (245)
Concurrent conditions
Heart disease (arrhythmias, ischemic heart disease) 28.0% (414)
Hypertension 23.4% (347)
Glaucoma 3.6% (54)
Urinary difficulties 8.6% (128)
Diabetes mellitus 8.1% (119)E. Umegaki et al.
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Subjects on antithrombotic therapy.  Subjects on anti-
thrombotic therapy accounted for 11.1% (98/883) of sub-
jects <65 years, and 24.6% (147/597) of those ≥65 years,
with significantly more elderly subjects on antithrombotic
therapy (p<0.0001, Table 3).
Subjects with risk factors for use of anticholinergic
agents.  The proportions of subjects with conditions where
anticholinergic agents should be avoided(heart disease,
hypertension, Glaucoma and/or prostatic hypertrophy) are
shown in Table 3. The proportion of subjects ≥65 years in
whom anticholinergic agents were contraindicated was
therefore 66.2% (395/597), significantly higher than that of
33.0% (291/883) for the <65 age group (p<0.0001, Table 3).
Subjects with risk factors for glucagon.  The proportions
of diabetic subjects, for whom glucagon is contraindicated,
was 5.8% (51/883) of subjects <65 years, and 11.4%
(68/597) of those ≥65 years, with diabetes significantly more
common in elderly subjects (p<0.0001, Table 3).
Subjects with risk factors for anticholinergic agents and/or
glucagon.  Almost half the study population had no con-
traindications for anticholinergic agents or glucagon
(Table 4). More patients had contraindications for anti-
cholinergic agents than glucagon, and less than 5% of the
study group had contraindications for both anticholinergic
agents and glucagon (Table 4).
Stratifying the risk groups according to age shows that
patients in the ≥65 years old group were less likely than
younger patients to have no contraindications (Table 5). This
difference is largely driven by a higher proportion of patients
with risk factors for anticholinergic agents in the elderly
group, as there was no significant difference between the
groups in the proportion of patients with risk factors for
glucagon.
Cardiovascular effects of endoscopic premedication
In the younger group, there were no significant changes
from baseline in hANP (Fig. 2) or hBNP (Fig. 3) levels
measured after endoscopy. However, in the elderly group,
Table 3. Analysis of risk factors for endoscopy-related complications or premedication contraindi-
cations according to age
All data were expressed as mean. Analyses were conducted using Fisher’s exact method (chi-square test).
<65 years old 
(n =8 8 3 )
≥65 years old 
(n = 597)
p value
First time endoscopy
29.9% 
(264)
23.1% 
(138)
0.0042
Lignocaine allergy
2.8% 
(25)
1.0% 
(6)
0.0160
Antithrombotic therapy
11.1% 
(98)
24.6% 
(147)
<0.0001
Heart disease
19.8% 
(175)
40.0% 
(239)
<0.0001
Hypertension
15.1% 
(133)
35.8% 
(214)
<0.0001
Glaucoma
2.5% 
(22)
5.4% 
(32)
0.0046
Prostatic hypertrophy
4.8% 
(42)
14.4% 
(86)
<0.0001
Diabetes
5.8% 
(51)
11.4% 
(68)
<0.0001
Table 4. Incidences of risk factors for anticholinergic agents
and glucagon in patients undergoing gastrointestinal
endoscopy
All data were expressed as mean. Analyses were conducted using
Fisher’s exact method (chi-square test).
*Anticholinergic Group vs Glucagon group (p<0.001)
**Anticholinergic Group vs Anticholinergic & Glucagon group
(p<0.001)
Risk 
(n = 1480)
No risk
49.9% 
(738)
Anticholinergic
41.6% 
(616)
Glucagon
3.8%* 
(56)
Anticholinergic & Glucagon
4.7%** 
(70)Risk Management for Gastrointestinal Endoscopy
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regardless of whether cardiovascular disease was present or
not, hANP level post-endoscopy was significantly greater
than at baseline (p<0.01), indicating an increased atrial load
associated with endoscopy (Fig. 2). In contrast, the increase
from baseline in hBNP level, indicating an increased
ventricular load, was only statistically significant (p<0.05)
in elderly patients with cardiovascular disease (Fig. 3).
Analysis of the cardiovascular effects of anticholinergic
agents and glucagon, administered as antispasmodic pre-
medication prior to endoscopy, in the elderly patients
showed that hANP levels were significantly higher fol-
lowing administration of anticholinergic agents, but the
change was not significant for glucagon premedication
(p<0.05) (Fig. 4). No statistically significant changes from
baseline were observed for hBNP levels after either anti-
cholinergic or glucagon premedication in elderly patients
(Fig. 5).
Discussion
The Japanese population is ageing rapidly. The Ministry
of Internal Affairs and Communications estimates that in
2008 there will be 27,790,000 Japanese aged over 65 years,
21.8% of the total population [9], and every year the number
and proportion of elderly sets a new record. Declining
physiological function accompanies the aging process,
arteriosclerosis and various degenerative changes. At the
same time, the prevalence of other comorbid diseases
increases, so special consideration is required to ensure the
safety of elderly patients when performing gastrointestinal
Table 5. Incidences of risk factors for anticholinergic agents and glucagon by age group in patients
undergoing gastrointestinal endoscopy
All data were expressed as mean. Analyses were conducted using Fisher’s exact method (chi-square test).
<65 years old 
(n =8 8 3 )
≥65 years old 
(n = 597)
p value
No risk
63.3% 
(559)
30.0% 
(179)
<0.0001
Anticholinergic
30.5% 
(269)
58.1% 
(347)
<0.0001
Glucagon
3.7% 
(33)
3.9% 
(23)
>0.9999
Anticholinergic & Glucagon
2.5% 
(22)
8.0% 
(48)
<0.0001
Fig. 2. Baseline and post-endoscopy human atrial natriuretic
peptide (hANP) levels in patients aged <65 years and
patients  ≥65 years with and without cardiovascular
disease. All data were expressed as mean ± SD. Analyses
were conducted using Student’s t test. In the ≥65 year
age group, hANP level post-endoscopy was significantly
greater than at baseline (p<0.01), regardless of whether
cardiovascular disease was present or not.
Fig. 3. Baseline and post-endoscopy human brain natriuretic
peptide (hBNP) levels in patients aged <65 years and
patients ≥65 years with and without cardiovascular dis-
ease. All data were expressed as mean ± SD. Analyses
were conducted using Student’s t test. In the ≥65 year
age group with cardiovascular disease, hBNP level was
significantly greater than at baseline (p<0.05).E. Umegaki et al.
J. Clin. Biochem. Nutr.
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endoscopy.
We developed this questionnaire from the viewpoint of
risk management associated with endoscopy. Questions
relating to known risk factors were included to identify
five groups considered high-risk during UGITE:
1)  subjects undergoing their first endoscopy, who are
thought to be at increased risk for complications;
2)  subjects allergic to lignocaine who are more likely to
develop anaphylactic shock, allergic reactions, or toxicity
[10];
3)  subjects taking antithrombotic therapy (e.g., warfarin,
ticlopidine, aspirin), prone to hemorrhage during investiga-
tions or treatment [11];
4) subjects with heart disease (arrhythmia, ischemic heart
disease), hypertension, glaucoma, or prostatic hypertrophy,
for whom anticholinergic agents are contraindicated
according to the Japanese Guidelines for Endoscopy in
Elderly Patients [12] ; and
5) subjects with Diabetes mellitus, for whom glucagon is
contraindicated.
The patient’s cardiorespiratory load is a major risk
associated with gastrointestinal endoscopy [13]. In this
study, no significant changes in hANP and hBNP, markers of
cardiac load, were seen before and after endoscopy in
younger subjects. In elderly subjects, however, hANP levels
increased significantly following the procedure, regardless
of whether cardiovascular disease was present or not,
indicating an increased atrial load associated with endo-
scopy. A significant rise in hBNP level was observed
following the procedure in elderly subjects with cardio-
vascular disease, indicating an increased ventricular load in
addition to the abovementioned atrial load.
If tissue biopsies are required during an endoscopic proce-
dure, it is important to consider whether the patient is taking
anticoagulant medication. In recent years, the use of anti-
thrombotic agents has increased markedly, particularly in
elderly patients, and the duration of the washout period for
these medications prior to an endoscopy has become a major
problem [14]. In this study, we were able to prevent
gastrointestinal hemorrhage associated with endoscopy by
confirming patients’ current medications using the pre-
procedural questionnaire.
Caution is also required to prevent problems associated
with endoscopic premedication. Reported complications
include anaphylaxis and allergic reactions caused by
lignocaine used for pharyngeal anesthesia [10], sudden
hemodynamic changes caused by anticholinergic agents
administered to inhibit gastrointestinal motility [15], and
secondary hypoglycemia caused by glucagon in diabetic
patients [16]. Apart from these complications, a number of
conditions have been identified as contraindications, or
requiring caution with use, for anticholinergic agents and
glucagon (Table 1).
Due to their parasympathetic blocking activity, anti-
cholinergic agents are contraindicated in patients with
glaucoma, prostatic hypertrophy, and cardiac conditions
Fig. 4. Baseline and post-endoscopy human atrial natriuretic
peptide (hANP) levels in patients aged ≥65 years follow-
ing premedication with anticholinergic agents or gluca-
gon. All data were expressed as mean ± SD. Analyses
were conducted using Student’s t test. In the elderly
patients (≥65 year age group) showed that hANP levels
were significantly higher following administration of
anticholinergic agents (p<0.05).
Fig. 5. Baseline and post-endoscopy human brain natriuretic
peptide (hBNP) levels in patients aged ≥65 years follow-
ing premedication with anticholinergic agents or gluca-
gon. All data were expressed as mean ± SD. Analyses
were conducted using Student’s t test. No statistically
significant changes from baseline were observed for
hBNP levels after either anticholinergic or glucagon pre-
medication in the elderly patients (≥65 year age group).Risk Management for Gastrointestinal Endoscopy
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such as arrhythmias. When anticholinergic agents are
contraindicated, glucagon is used as an alternative premedi-
cation. However, glucagon should be used with caution in
diabetic patients due to its hyperglycemic effect [16]. Like
anticholinergic agents, glucagon acts directly on the smooth
muscle of the gastrointestinal tract to inhibit peristaltic
activity [17–19], and should be administered with caution
to patients with cardiac disease. Compared with anti-
cholinergic agents, however, the effects of glucagon on
hemodynamic parameters such as blood pressure and heart
rate are minimal [20]. In this study, we measured hANP and
hBNP levels to compare the cardiovascular effects of
anticholinergic agents and glucagon, both used as anti-
spasmodic premedication for gastrointestinal endoscopy. We
found the rise in hANP levels, indicating increased atrial
load, was significant in elderly patients given anticholin-
ergic agents, but not in those given glucagon. Accordingly,
the premedication best suited to the individual patient’s
medical condition should be selected in accordance with
the information provided by the questionnaire, and informed
consent obtained before performing gastrointestinal endo-
scopy [21].
Saito et al. applied a preprocedural questionnaire similar
to ours, defining the contraindications for anticholinergic
agents as “hypertension, arrhythmia, ischemic heart disease,
glaucoma and prostatic hypertrophy”, with glucagon con-
traindicated in patients with “diabetes mellitus” [22]. Of 416
subjects who underwent investigations of the gastrointestinal
tract (365 endoscopies, 51 barium contrast radiography),
anticholinergic agents were contraindicated in 35% of all
subjects, and more than half (53%) of elderly subjects aged
65 years and older [22]. In the current large-scale study, we
analyzed background factors using a questionnaire in 1480
subjects undergoing UGITE. The proportion of subjects in
whom anticholinergic agents were contraindicated was
significantly higher in subjects aged 65 years and older than
in those under 65 years. In particular, more than half of
elderly subjects had contraindications for anticholinergic
agents, significantly higher than in subjects aged under 65
years. There was no significant difference between age
groups in the proportion of subjects in whom glucagon was
contraindicated.
From the point of view of risk management and preven-
tion of complications associated with gastrointestinal endo-
scopy, our results show that taking a thorough history before
the procedure will reveal important patient background
factors, including underlying medical conditions and medi-
cations, thus facilitating selection of the appropriate pre-
medication for that patient. In particular, in many elderly
patients glucagon should be selected as the premedication
for safer endoscopies because of its narrower range of
complications and precautions for use in this population.
We analyzed risk groups for endoscopy using a question-
naire in 1480 subjects undergoing UGITE. Taking a detailed
history before UGITE with the aid of a questionnaire at the
same time as informed consent is obtained, is extremely
useful in terms of risk management and selection of the
appropriate premedication.
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